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Abstract
We assessed cognitive function of female rheumatoid arthritis (RA) patients and analyze the determinants, with special 
focus on cerebrovascular morphology. Sixty methotrexate (MTX-) or biologic-treated RA patients and 39 healthy controls 
were included in a cross-sectional study. Smoking habits, alcohol intake and time spent in education were recorded. Stand-
ard measures were performed to assess cognitive function (Montreal Cognitive Assessment, MOCA; Trail Making Test, 
TMT; Victoria Stroop Test, VST; Wechsler Adult Intelligence Scale, WAIS; Benton Visual Retention test, BVRT), depres-
sion (Beck Depression Inventory, BDI), anxiety (State-Trait Anxiety Inventory, STAIT/S) and general health status (Short 
Form 36, SF-36). Mean disease activity (28-joint Disease Activity Score, mDAS28; erythrocyte sedimentation rate, mESR; 
C-reactive protein, mCRP) of the past 12 months was calculated; anti-cyclic citrullinated peptide (CCP) and rheumatoid 
factor (RF) were assessed. Cerebral vascular lesions and atrophy, carotid intima–media thickness (cIMT) and plaques, as 
well as median cerebral artery (MCA) circulatory reserve capacity (CRC) were assessed by brain magnetic resonance imag-
ing (MRI), carotid ultrasound and transcranial Doppler, respectively. Cognitive function tests showed impairment in RA vs 
controls. Biologic- vs MTX-treated subgroups differed in TMT-A. Correlations were identified between cognitive function 
and depression/anxiety tests. WAIS, STAIS, STAIT and BDI correlated with most SF-36 domains. Numerous cognitive 
tests correlated with age and lower education. Some also correlated with disease duration, mESR and mDAS28. Regarding 
vascular pathophysiology, cerebral vascular lesions were associated with VST-A, carotid plaques with multiple cognitive 
parameters, while MCA and CRC with MOCA, BVRT and BDI. RA patients have significant cognitive impairment. Cognitive 
dysfunction may occur together with or independently of depression/anxiety. Older patients and those with lower education 
are at higher risk to develop cognitive impairment. Cognitive screening might be a useful tool to identify subgroups to be 
further investigated for cerebrovascular pathologies.
Keywords Rheumatoid arthritis · Cognitive dysfunction · Cerebrovascular disease · Transcranial Doppler · Carotid artery · 
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Introduction
Rheumatoid arthritis (RA) may involve the vascular and 
nervous systems [1, 2]. There is increased risk of ischemic 
stroke, especially in elderly RA patients with long-standing 
disease [3]. We have recently reported abnormalities in 
the cerebral circulation in transcranial Doppler (TCD) and 
vascular lesions by brain MRI in RA [4]. Functional MRI 
revealed the association of inflammation with brain struc-
ture and connectivity in RA [5]. Depression and anxiety are 
present in two-third of RA patients [6–8].
Cognitive function includes orientation, attention/con-
centration, judgment/problem solving, memory, verbal, 
visual/spatial and executive functions [9, 10]. RA patients 
may significantly underperform on cognitive function tests 
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compared to controls [9, 11–15]. Even mild impairment may 
influence the functional capacity and quality of life of RA 
patients [9, 13, 16, 17]. It affects reactivity to pain, compli-
ance to and effectiveness of therapy [9].
In general, both inflammation itself that may also affect 
the brain [5, 9, 17] and accelerated atherosclerosis and 
increased cardiovascular (CV) pathology also driven by 
systemic inflammation [13, 17–19] may cause cognitive 
impairment in RA. Pain, stress, fatigue, sleep disturbances, 
depression and anxiety may also be involved in RA-associ-
ated cognitive decline [7, 9, 13]. Methotrexate (MTX) and 
corticosteroids have been associated with cognitive impair-
ment [9, 20, 21]. As inflammation is involved in cognitive 
dysfunction in RA, the control of disease activity may be 
beneficial for the patients [22, 23].
We wished to assess cognitive function in a subset of 
Hungarian patients with RA compared to healthy controls 
using multiple standardized cognitive tests in parallel with 
imaging assessment of cerebrovascular morphology. Regard-
ing explanatory factors, we focused on six major areas: some 
demographic parameters (age, educational level), lifestyle 
factors (smoking, alcohol intake), disease characteristics 
(duration, seropositivity, activity), treatment subgroups 
(MTX, biologic), physical and mental health status (SF-
36), mood problems (depression, anxiety) and cerebrovas-
cular morphology [carotid atherosclerosis, cerebrovascular 
reserve capacity (CRC) of median cerebral artery (MCA), 
brain MRI]. The novelty of our study is that we used multi-
ple tests of cognitive function and we associated these tests 
with cerebrovascular imaging.
Patients and methods
Patients and controls
Sixty female RA patients undergoing regular follow-ups 
at the Borsod County Teaching Hospital, Miskolc were 
selected. The inclusion criteria were female patients aged 
18 or over; definitive diagnosis of RA; stable dose of MTX, 
corticosteroids and biologics for at least 6 months prior to 
the study; and informed consent. The exclusion criteria 
were pregnancy and/or breast feeding; any previous vas-
cular events including cerebrovascular diseases, as well as 
mental disorders; history of skull trauma; known depression 
and other mood disorders; implanted metal; claustropho-
bia. Twenty patients were biologic naive. They had been 
receiving MTX for a mean 7.2 ± 4.9 (range 2–15) years in 
an average dose of 14.1 ± 4.4 (range 5–25) mg per week. We 
selected 40 female patients receiving biologics [20 inflixi-
mab (IFX) and 20 tocilizumab (TCZ)] as first-line biologic 
treatment at the time of the survey, in combination with 
MTX, for a mean duration of 4.0 ± 2.0 (range 1–10) years. 
We selected intravenously administered biologics to increase 
compliance and therapy control. Moreover, we had more 
time to perform the psychologic and other diagnostic tests. 
The doses of MTX and biologics had been stable for at least 
3 months prior to the study. Disease activity (DAS28-ESR) 
was determined in all RA patients every 3 months; thus, the 
mean values of the past 5 visits (12 months) were calculated 
and used in our analyses (Table 1).
For this study, a convenience sample of 39 healthy female 
individuals was chosen as the control group. These controls 
participated in a carotid ultrasound screening program car-
ried out in the Borsod County region by some of the authors. 
Controls had the same inclusion and exclusion criteria as the 
RA patients. The age of controls (60.2 ± 6.7 years) was not 
significantly different from that of RA patients (Table 1). 
As normative data with the Short Form 36 (SF-36) general 
health status measure are available for the Hungarian general 
population, RA patients’ SF-36 scores were compared to the 
gender- and age-matched population norm [24].
We assessed smoking habits, alcohol consumption during 
the past 2 years and the number of years in education (school 
years) by a questionnaire (Table 1).
Ethical approval (No. 1046-63/2015) was obtained from 
the Regional/Institutional Review Board of Miskolc Uni-
versity. All patients and controls signed informed consent. 
The study was performed according to the Declaration of 
Helsinki.
Tests of cognitive function and depression/anxiety
The following standardized tests also translated to Hungar-
ian were used (Table 2) [25]:
Mental capabilities The Montreal cognitive assessment 
(MOCA) test is a screening tool to determine mental capa-
bilities in general and for determining mild cognitive impair-
ment. The higher values indicate better cognitive function 
(range 0–30); a score of ≥ 26 is considered as normal [26].
Attention/concentration The Digit Symbol subtest of the 
Wechsler Adult Intelligence Scale (WAIS) provides infor-
mation on visuo-perceptual functions, fine visual-motor 
dexterity and speed. The number of correct symbols repro-
duced within the time limit is measured. Numbers are then 
converted to Q points (age-adjusted standard scores in the 
Hungarian version) [27, 28]. Trail making test (TMT) meas-
ures the visual attention, speed of visual processing, mental 
flexibility, and executive functions. In part A of the TMT 
(TMT-A) assessing visuomotor processing speed, num-
bers are presented on a page in random array. The patient 
is instructed to connect the numbers in ascending order as 
quickly as possible. Part B (TMT-B) determines mental flex-
ibility and measures the control and executive function of 
the frontal lobe of the brain. Here, both numbers and letters 
are on the sheet and the examinee must alternate connecting 
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numbers and letters in sequence. The score on each part 
is the time required to complete the task. The shorter time 
indicates better function [25].
Executive function The Victoria Stroop Test (VST) is a 
brief version of the Stroop task. The Stroop task measures 
the cognitive control by assessing the ease with which a 
Table 1  General characteristics 
and laboratory markers of 
assessed RA patients and 
controls
amDAS28 and mESR indicate the means of the last 5 values
CCP cyclic citrullinated peptide, CRP C-reactive protein, DAS28 28-joint disease activity score, ESR 
erythrocyte sedimentation rate, MTX methotrexate, RA rheumatoid arthritis, RF rheumatoid factor
RA (total) RA (MTX) RA (biologic) Controls
n 60 20 40 39
Age (years) 60.7 ± 9.5 61.3 ± 9.1 60.4 ± 9.8 60.2 ± 6.7
Sex (females) 60 20 20 39
Disease duration (years) 11.6 ± 7.6 11.8 ± 8.6 11.6 ± 7.1 –
RF positivity (%) 70% 82% 66% –
Anti-CCP positivity (%) 65% 75% 64% –
Patients with erosions on hand/
feet X-ray (%)
54/60 (90) 18/20 (90) 36/40 (90)
MTX duration (years) 6.7 ± 4.1 7.2 ± 4.9 6.4 ± 3.6 –
MTX dose (mg/week) 14.9 ± 5.5 14.1 ± 4.4 15.3 ± 5.9 –
Biologic duration (years) 4.0 ± 2.0 – 4.0 ± 2.0 –
mDAS28-ESRa 2.50 ± 0.87 2.89 ± 0.80 2.30 ± 0.78 –
mESR (mm/h)a 17.7 ± 15.9 20.3 ± 16.6 16.4 ± 15.7 –
hsCRP (mg/l) 5.2 ± 7.7 8.5 ± 10.9 3.5 ± 4.7 –
Time at school (years) 11.4 ± 3.0 12.5 ± 2.7 10.8 ± 3.0 12.3 ± 1.8
Smoking (%) 10/60 (16.6) 5/20 (25.0) 5/40 (12.5) 3/39 (7.7)
Alcohol consumption (%) 5/60 (8.3) 2/20 (10.0) 3/40 (7.5) 10/39 (25.6)
Current workability (%) 9/60 (15) 6/20 (30) 3/40 (7.5) 37 (95)
Table 2  Results of cognitive function and depression/anxiety tests in RA patients and controls
Significantly different values are in bold italics
BDI Beck depression inventory, BVRT Benton visual retention test, MOCA montreal cognitive assessment test, MTX methotrexate, RA rheuma-
toid arthritis, STAI state–trait anxiety inventory, TMT trail making test, VST victoria stroop test, WAIS Wechsler Adult Intelligence Scale
a Abnormal column indicates whether higher (↑) or lower (↓) values are abnormal
Abnor-
mala (↑ 
or ↓)
RA (total) RA (MTX) RA (biologic) Controls p (RA vs control) p (MTX 
vs con-
trol)
p (biologic 
vs control)
p (MTX 
vs bio-
logic)
n 60 20 40 39
Cognitive function tests
MOCA total (n) ↓ 23.3 ± 3.8 24.6 ± 2.2 22.6 ± 4.2 25.6 ± 2.4 0.002 0.188 0.001 0.089
TMT-A time (s) ↑ 69.0 ± 26.3 57.9 ± 15.4 76.2 ± 29.7 53.1 ± 14.3 0.029 0.420 0.007 0.041
TMT-B time (s) ↑ 108.2 ± 48.4 98.4 ± 38.9 113.8 ± 56.7 76.3 ± 22.7 0.048 0.058 0.140 0.819
VST-A time (s) ↑ 20.6 ± 9.3 18.8 ± 7.9 21.6 ± 9.8 18.0 ± 10.1 0.040 0.450 0.019 0.232
VST-B time (s) ↑ 23.0 ± 9.6 20.7 ± 8.2 24.1 ± 10.1 19.3 ± 5.8 0.051 0.994 0.007 0.127
VST-C time (s) ↑ 36.9 ± 18.1 33.9 ± 13.9 38.4 ± 19.9 29.7 ± 9.3 0.075 0.308 0.069 0.504
WAIS total (n) ↓ 25.4 ± 13.3 28.0 ± 14.1 24.1 ± 12.9 28.5 ± 12.6 0.003 0.094 0.006 0.455
BVRT total (n) ↓ 6.58 ± 1.91 6.75 ± 1.87 6.50 ± 1.90 7.67 ± 1.98 0.005 0.074 0.006 0.662
BVRT error (n) ↑ 3.67 ± 0.93 3.50 ± 1.15 3.75 ± 0.81 3.54 ± 1.07 0.655 0.860 0.456 0.412
Depression/anxiety tests
STAIS (n) ↑ 45.5 ± 8.5 43.4 ± 9.0 46.6 ± 8.1 36.9 ± 9.1 < 0.001 0.012 < 0.001 0.134
STAIT (n) ↑ 48.0 ± 11.0 46.0 ± 11.6 48.9 ± 10.7 41.1 ± 9.0 0.004 0.183 0.002 0.384
BDI (n) ↑ 13.2 ± 8.8 12.3 ± 9.2 13.6 ± 8.7 8.9 ± 6.5 0.023 0.251 0.015 0.432
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person can maintain a goal in mind and suppress a habitual 
response in favor of a less familiar one (response inhibi-
tion). VST contains 24 items in each of the following condi-
tions: naming the color of dots (VST-A), of neutral words 
(VST-B), and of color words printed in contrasting colors 
(VST-C). We determined the time in seconds. In general, 
the VST tests assess executive functions [25]. TMT-B (see 
above) also assesses executive function [25].
Memory The Benton Visual Retention Test (BVRT) was 
used to assess the patient’s immediate visual memory and 
visuo-constructive skills. In the BVRT, 10 pictures with geo-
metric figures are shown one after the other and the patient 
has to draw the designs as accurately as possible. Adminis-
tration A (10 s exposure to each card with immediate recall 
by drawing) was used. The total score corresponds to the 
number of correct reproductions (maximum 10). The error 
score indicates the number of errors. Evidently, more cor-
rect reproductions and less errors indicate intact skills [29].
Anxiety The Spielberger State-Trait Anxiety Inventory 
(STAI) is a commonly used self-scored measure of trait and 
state anxiety. It is composed of dot, neutral word and color 
word tasks. Both the time of task completion and the number 
of errors have been recorded. STAIS indicates state (cur-
rent status) and STAIT measures trait (general status) [30]. 
Lower STAIS or STAIT values represent less trait and state 
anxiety.
Depression The Beck Depression Inventory (BDI) is a 
self-report rating inventory that measures characteristic atti-
tudes and symptoms of depression [31]. Higher BDI values 
represent higher degree of depression.
SF‑36 test of general health status
Short Form 36 (SF-36) measures general health status [32, 
33]. The SF-36v2 questionnaire consists of 36 questions 
and provides scores for 8 individual subscales (weighted 
sums of the respective questions): physical function (PF), 
role physical (RP), bodily pain (BP), global health (GH), 
vitality (VT), social function (SF), role emotional (RE) 
and mental health (MH). The score range of each scale 
is between 0 and 100; the lower the score the more dis-
ability. Scores for each domain were calculated and were 
combined to form the physical component summary (PCS; 
PF + RP + BP + GH) and mental component summary 
(MCS; VT + SF + RE + MH) scores [32, 33]. In this study, 
the paper-based, Hungarian validated version of the SF-36v2 
was used [24].
Laboratory assessments and disease activity
Serum IgM RF and high-sensitivity CRP (hsCRP) were 
assessed by quantitative nephelometry (Cobas Mira Plus, 
Roche), using RF and CRP reagents, respectively (both 
Dialab, Vienna, Austria). RF levels > 50 IU/ml indicated 
seropositivity and hsCRP levels > 5 mg/l were considered 
elevated. Anti-CCP autoantibodies were detected in serum 
samples using the second generation Immunoscan-RA CCP2 
ELISA test (Euro Diagnostica, Arnhem, The Netherlands). 
The assay was performed according to the instructions of 
the manufacturer. A concentration > 25  IU/ml indicated 
seropositivity. Erythrocyte sedimentation rate (ESR) was 
determined by the traditional Westergren method (mm/h). 
DAS28-ESR was determined in all RA patients and mean of 
the last 5 ESR (mESR) and DAS28 values (mDAS28) was 
also calculated (Table 1).
Transcranial Doppler assessment
Transcranial Doppler (TCD) assessment of the MCA vessels 
was performed as described by us before [4]. In brief, MCAs 
were assessed by TCD using a Multi-Dop T Digital (DWL 
Compumedics GmbH, Singen, Germany) device. Among 
TCD indices, CRC reflects the physiological vasoconstric-
tive and vasodilatory function of precapillary (resistance) 
arteries. Normally, the increase in CRC after stimuli causing 
vasodilation is > 30% [4, 34, 35]. TCD was performed by a 
single technician (M.S.) and validated by a neuroradiologist 
(C.O.).
Carotid artery ultrasound examination
Common carotid artery (CCA) assessments were carried out 
using a duplex ultrasound system (Vivid E, GE Healthcare) 
using a 8 MHz linear array transducer (GE Probe 8L-RS) 
as described by us elsewhere [4, 36]. Longitudinal high-
resolution B-mode ultrasound scans were employed over 
both right and left CCA and were R-synchronized and 
recorded. Carotid artery intima–media thickness (cIMT; 
mm) was defined as the distance between the first and sec-
ond echogenic lines from the lumen, taking the average of 
five measurements on both sides. All visible plaques were 
also detected. Assessments were performed by a single 
observer (AS).
Brain MRI investigations
Altogether 49 out of the 60 RA patients also underwent 
brain MRI studies (Siemens Magnetom Verio 3T, Siemens, 
Munich, Germany) to assess focal vascular lesions, emolli-
tion and atrophy. All MRI scans were performed by a single 
radiologist (LK) and also read by a neuroradiologist (CO). 
Hyperintense lesions detected by T2 and flair sequences not 
characteristic for any white matter diseases were considered 
vascular lesions. A global cortical atrophy score was used 
as follows: 0, no atrophy; 1, mild atrophy with opening of 
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sulci; 2, moderate atrophy with volume loss of gyri; 3, severe 
atrophy.
Statistical analysis
Statistical analysis was processed with IBM SPSS 22 soft-
ware. Data are expressed as the mean ± SD and frequen-
cies and percentages. Normality of data was assessed by 
Kolmogorov–Smirnov test. Continuous variables were 
compared by Mann–Whitney test. Simple correlations were 
determined by Spearman’s analysis. Multiple linear regres-
sion analysis using the backward method was used to deter-
mine correlations and independent associations between 
parameters. Cognitive tests were the dependent variables 
and several other parameters were independent variables. 
The β standardized linear coefficients showing linear cor-
relations between two parameters were determined. The B 
(+ 95% CI) regression coefficient indicated independent 
association between the dependent and independent variable 
during changes. P values < 0.05 were considered significant.
Results
Basic characteristics of RA patients and controls
The major characteristics of the patients are shown in 
Table 1. Their mean age was 60.7 ± 9.5 (range 27–78) years 
and their mean disease duration was 11.6 ± 7.6 (range 2–36) 
years. Altogether 70% were IgM rheumatoid factor (RF) 
positive and 65% were ACPA (anti-CCP2) positive.
The number of “school years” was not different between 
RA patients and controls. However, it was lower in bio-
logic (10.8 ± 3.0 years) compared to MTX-treated patients 
(12.5 ± 2.7 years; p = 0.014) and controls (12.3 ± 1.8 years; 
p = 0.004) (Table 1).
There were more smokers among the total RA, bio-
logic- and MTX-treated RA groups compared to controls 
(p < 0.05). One-fourth of controls but only 8.3% of RA 
patients regularly consumed alcohol (p < 0.05) (Table 1).
CCA plaques were detected in 33 RA patients (55%). 
Altogether 46.9% of RA patients but only 23.5% of con-
trols had at least one MRI vascular lesion in their left hemi-
sphere (p = 0.030). Similarly, 23 patients (46.9%), but only 
20.6% of controls had MRI lesions in their right hemisphere 
(p = 0.014). Altogether 26.5% of RA patients and 2.9% of 
controls had cerebral atrophy (p = 0.005) (data not shown).
Results of cognitive tests, depression and anxiety 
inventories
The MOCA total score was significantly lower (abnor-
mal) in all RA (p = 0.002) and in biologic-treated patients 
(p = 0.001) compared to controls (Table  2). MOCA 
score < 26 (indicating cognitive impairment) was observed 
in 63%, 50%, 70% and 46% of patients in the total RA, MTX, 
biologic sub-groups and controls, respectively (all RA vs 
controls: p = 0.032; data not shown).
All (p = 0.029) and biologic-treated RA patients 
(p = 0.007) had longer TMT-A times than controls. Biologic-
treated patients also required longer time vs MTX-treated 
ones (p = 0.041). In TMT-B, RA patients also needed more 
time than controls (p = 0.048) (Table 2).
In VST-A, RA patients (p = 0.040) and the biologic-
treated subset (p = 0.019) needed more time to complete the 
task than controls. In VST-B, biologic-treated RA patients 
required more time vs controls (p = 0.007) (Table 2).
WAIS digit symbol scores were significantly lower 
(abnormal) in the total (p = 0.003) and biologic-treated RA 
groups (p = 0.006) compared to controls (Table 2).
In BVRT, the number of correct reproductions was signif-
icantly lower in the full RA cohort (p = 0.005) and biologic-
treated patients (p = 0.006) compared to controls. There were 
no differences in BVRT errors (Table 2).
Regarding anxiety/depression tests, STAIS values were 
significantly higher (abnormal) in all (p < 0.001), MTX-
treated (p = 0.012) and biologic-treated patients (p < 0.001) 
vs controls. STAIT values were also higher in the total 
(p = 0.004) and biologic-treated RA group (p = 0.002) vs 
controls (Table 2). BDI values were significantly higher 
(abnormal) in all (p = 0.023) and biologic-treated patients 
(p = 0.015) vs controls (Table 2). As STAIT and BDI are 
anxiety/depression tests, we performed an additional anal-
ysis to determine the additional value of STAIT and BDI 
tests in studying cognitive function of RA patients. Here, 
RA patients with normal performance in all cognitive tests 
were considered those with “normal cognitive function”. If 
at least one test gave abnormal result, that individual had 
cognitive abnormality. Based on this assessment, out of the 
60 RA patients, 25 had cognitive impairment and 35 had 
normal cognitive function. When these two RA groups were 
compared based on STAIT and BDI, those with cognitive 
impairment have significantly higher STAIT (p = 0.011) and 
BDI (p = 0.012) compared to those performing well in all 
tests. Controls did not have such differences. Thus, depres-
sion and anxiety as measured by BDI and STAIT, respec-
tively, can further differentiate between RA patients who 
had at least one other abnormal test results and those with 
normal cognitive test performance.
We used data from the previous SF-36 Hungarian popu-
lation norm study representing women with 58-61 years of 
age that corresponds to our RA subset [24]. SF-36 scores 
were lower in RA patients vs controls in all domains except 
RE. Three out of the four mental domains of the SF-36 (VT, 
SF and MH) were impaired in RA patients and RA subsets 
compared to controls (p < 0.05) (Fig. 1).
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Correlations among cognitive function tests in RA 
patients
All cognitive function tests were correlated with each other in 
RA patients. As many of them assess somewhat overlapping 
characteristics, numerous correlations could be identified. In 
general, most cognitive test results correlated with many others 
(data not shown).
Correlations between cognitive function and SF‑36 
in RA patients
STAIS, STAIT and BDI values showed significant inverse 
correlations with all 8 SF-36 domains, as well as with MCS 
(p < 0.05). WAIS Digit Symbol values exerted positive corre-
lations with 7 SF-36 domains, PCS and MCS (p < 0.05) (data 
not shown).
Correlations between cognitive function and other 
parameters in RA patients
Longer TMT-A, TMT-B, VST-A, VST-B, VST-C times, 
more BVRT errors and lower WAIS scores correlated with 
age (p < 0.05). Longer VST-A time correlated with disease 
duration (p = 0.027), while STAIT correlated with mESR 
(p = 0.006) and mDAS28 (p = 0.018). MOCA, STAIS, 
STAIT, BDI values, VST-A, VST-B and VST-C times, 
WAIS and BVRT total scores and BVRT error numbers 
showed associations with years in education (p < 0.05) 
(Table 3).
Associations between cognitive function 
and vascular abnormalities in RA patients
Left MCA CRC positively correlated with MOCA 
(p = 0.016) and inversely with BDI (p = 0.008). Right MCA 
CRC exerted positive correlation with BVRT total values 
(p = 0.033). Right cIMT inversely correlated with WAIS 
Digit Symbol scores (p = 0.024) (Table 3). RA patients 
with right carotid plaques had higher STAIS, STAIT val-
ues, longer VST-C times and lower WAIS scores (p < 0.05). 
Patients with left carotid plaques had higher STAIS, STAIT, 
BDI scores, longer TMT-A and VST-C times, and lower 
WAIS scores (p < 0.05) (Table 4). Patients with MRI vascu-
lar lesions had longer VST-A times (p = 0.032), while those 
with brain atrophy had lower WAIS scores (Table 4).
Determinants of cognitive function in RA patients
Univariate and multiple regression analyses were performed 
to assess independent determinants of cognitive function 
(Table 5).
In the univariate analysis, numerous tests correlated with 
age and/or school years (p < 0.05). STAIS, STAIT, TMT-A 
time, VST-C time and WAIS Digit Symbol score were asso-
ciated with the presence of carotid plaques (p < 0.05). WAIS 
scores also correlated with right cIMT (p = 0.024). VST-A 
time correlated with the presence of MRI vascular lesions 
(p = 0.006). BDI and BVRT total scores associated with 
left and right MCA CRC, respectively (p < 0.05). STAIT 
correlated with mESR (p = 0.009) and mDAS28 (p = 0.02). 
Biologic- vs MTX-treated patients had longer TMT-A times 
(p = 0.03) (Table 5).
In the multiple regression analysis of RA patients, age 
was independent predictor of TMT-A time (p = 0.001), 
VST-B time (p = 0.005), VST-C time (p = 0.001) and 
WAIS scores (p = 0.001). School years determined MOCA 
(p = 0.006), STAIS (p < 0.001), BDI (p = 0.001), BVRT 
total scores (p < 0.001) and errors (p < 0.001). The pres-
ence of left carotid plaques determined STAIT (p = 0.036), 
while that of MRI lesions predicted longer VST-A times 
(p = 0.001). The use of biologics vs MTX was an independ-
ent predictor of TMT-A times (p = 0.016) (Table 5).
Discussion
We cross-sectionally assessed cognitive functions and 
depression/anxiety in female RA patients compared to gen-
der- and age-matched healthy individuals using standard val-
idated measures. Moreover, we aimed to explore associations 
Fig. 1  Results of the SF-36 test in all, methotrexate (MTX)- and bio-
logic-treated rheumatoid arthritis (RA) patients and controls. The 8 
domains are: physical function (PF), role physical (RP), bodily pain 
(BP), global health (GH), vitality (VT), social function (SF), role 
emotional (RE) and mental health (MH)
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between cognitive decline and RA-related parameters, CV 
and cerebrovascular pathophysiology, quality of life and 
therapy. Among the domains of cognitive function [9, 10], 
we assessed attention/concentration (WAIS, TMT-A, TMT-
B), memory (BVRT), executive functions (TMT-B, VST). 
We applied MOCA as a screening tool. We also compared 
cognitive dysfunction with depression (BDI) and anxiety 
(STAI). The novelty of our study is that we used many tests 
of cognitive function and we associated these tests with cer-
ebrovascular imaging including TCD, carotid ultrasound and 
brain MRI.
MOCA score, TMT-A, TMT-B, VST-A and VST-B 
times, WAIS Digit Symbol scores and the number of correct 
reproductions in BVRT were significantly abnormal in RA 
patients vs controls. Our results confirm that RA is associ-
ated with cognitive impairment [9, 11, 13].
As different domains of cognitive function are interre-
lated [9, 10], it is not surprising that results of the various 
cognitive function tests correlated with each other in RA. 
Depression and anxiety are common among RA patients [6, 
7]; however, some domains of cognitive dysfunction did not 
correlate with BDI or STAI suggesting that cognitive decline 
in RA also involves other factors. Although cognitive func-
tion and depression/anxiety have been tested in the same 
RA patients [15, 37], we did not find any extensive studies 
correlating these entities.
Three out of 4 SF-36 mental domains were impaired in 
RA patients. The WAIS screening test showed association 
with 7 out of 8 SF-36 domains. TMT-A and TMT-B times 
also correlated with some, mainly physical SF-36 domains. 
Moreover, STAIS, STAIT and BDI values were associated 
with all 8 SF-36 domains suggesting that, in RA, both cog-
nitive dysfunction and depression/anxiety may have nega-
tive impact on the general health status of the patients. We 
have found only one study that analyzed the associations 
of cognitive function with SF-36 in RA. Kim et al. [38] 
Table 3  Significant correlations between cognitive test results and other parameters in RA patients
BDI Beck depression inventory, BVRT Benton visual retention test, cIMT carotid intima–media thickness, CRC circulatory reserve capacity, 
DAS28 28-joint disease activity score, ESR erythrocyte sedimentation rate, MOCA Montreal Cognitive Assessment test, STAI state–trait anxiety 
inventory, TMT Trail Making Test, VST Victoria Stroop Test, WAIS Wechsler Adult Intelligence Scale
a Abnormal column indicates whether higher (↑) or lower (↓) values are abnormal
b mDAS28 and mESR indicate the means of the last 5 values
Abnor-
mala (↑ 
or ↓)
Age Disease duration mESRb mDAS28b School years CRC (left) CRC (right) cIMT (right)
Cognitive function tests
MOCA (n) ↓ R = 0.334
p = 0.009
R = 0.445
p = 0.016
TMT-A time (s) ↑ R = 0.525
p = 0.002
TMT-B time (s) ↑ R = 0.492
p = 0.013
VST-A time (s) ↑ R = 0.366
p = 0.004
R = 0.285
p = 0.027
R = − 0.318
p = 0.013
VST-B time (s) ↑ R = 0.424
p = 0.001
R = − 0.398
p = 0.002
VST-C time (s) ↑ R = 0.486
p < 0.001
R = − 0.345
p = 0.007
WAIS total (n) ↓ R = − 0.311
p = 0.001
R = 0.456
p < 0.001
R = − 0.291
p = 0.024
BVRT total (n) ↓ R = 0.378
p = 0.003
R = 0.342
p = 0.033
BVRT error (n) ↑ R = 0.290
p = 0.025
R = − 0.369
p = 0.004
Depression/anxiety tests
STAIS (n) ↑ R = − 0.489
p < 0.001
STAIT (n) ↑ R = 0.354
p = 0.006
R = 0.307
p = 0.018
R = − 0.368
p = 0.004
BDI (n) ↑ R = − 0.425
p = 0.001
R = − 0.481
p = 0.008
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reported an independent association of MCS with MOCA. 
Shin et al. [11] used 16 cognitive indices and found relation-
ship between cognitive and functional limitations. However, 
studies exploring the impact of cognitive impairment on 
health-related quality of life in RA are, on the whole, scarce 
and deserve further investigation.
In our RA cohort, cognitive function tests were also cor-
related with other parameters, such as age, disease duration, 
school years, mESR or mDAS28. Shin et al. [13] and Lee 
et al. [39] also associated cognitive impairment with low 
education and disease activity, respectively.
As atherosclerosis has been implicated in cognitive 
impairment in RA [9, 13], we also determined cerebral vas-
cular lesions and atrophy, carotid atherosclerosis and CRC. 
We indeed found correlations between these vascular patho-
logic alterations and cognitive dysfunction. As described 
above, functional MRI [40] showed pathological cerebral 
alterations in RA. In non-RA, stroke patients, other investi-
gators also found associations between cognitive decline and 
carotid atherosclerosis [41]. Cerebral blood flow in associa-
tion with cognitive function has not yet been assessed in RA 
before. In non-RA studies, cerebral arterial circulation was 
associated with cognitive impairment [42, 43].
RA patients treated with biologics usually resemble a 
more severe form of disease than those controlled by MTX 
only. In our study, TMT-A times were longer in biologic- 
vs MTX-treated patients. Although some studies suggest 
that MTX may itself cause cognitive impairment [20], it is 
possible that the severity of RA may even be more impor-
tant in this respect. Meade et al. [20] reported that patients 
taking higher doses of MTX have lower cognitive perfor-
mance; however, it was still in the normal range. They also 
emphasized that due to the various treatment protocols, one 
needs to be cautious when drawing conclusions on the pos-
sible effects of anti-rheumatic drugs on cognition [9, 20]. 
Although sustained inflammation may be involved in cogni-
tive decline in RA [9, 17], only very few studies evaluated 
the longitudinal effects of anti-rheumatic drugs on cogni-
tive function. In the open-label study of Raftery et al. [22], 
adalimumab improved full scale, verbal and performance IQ 
in parallel with improvements of DAS28. Camara et al. [44] 
reported that centrally administered etanercept improved 
anxiety-like behavior in mice. Khandaker et al. [23] pre-
sented a protocol of a trial initiated in 2018, where behavio-
ral and cognitive measures will be evaluated in tocilizumab-
treated patients. In addition to pharmacotherapy, tailored 
cognitive behavioral therapy introduced in early RA was 
found to be beneficial in various studies [45, 46].
Our study may have strengths and limitations. Our study 
is rather comprehensive applying numerous different cog-
nitive function tests in the context of clinical, laboratory 
factors, brain vascular lesions, carotid atherosclerosis, CRC 
and quality of life. The limitations of our study include Ta
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the relatively low number of patients and healthy controls 
matched for many but not all potentially relevant characteris-
tics. Hence, we suggest to consider our results as explorative 
rather than conclusive and further studies involving larger 
samples, representative for the RA population are encour-
aged. However, feasibility issues may arise on performing 
imaging technologies alongside the standard cognitive tests 
in large groups of patients and controls, one of the strengths 
of our study. Given the cross-sectional design, the effect of 
anti-rheumatic therapy on cognitive function could not be 
longitudinally analyzed; this is an important area for fur-
ther research. While laboratory biomarkers and quality of 
life could be numerically determined, alcohol intake, smok-
ing habits and education were rather estimated. Applying 
Table 5  Linear regression analysis of cognitive function test results and other parameters in RA patients
Linear regression, backward method, β standardized linear coefficient, B (+95% CI) regression coefficient. See text for abbreviations and expla-
nations
a mDAS28 and mESR indicate the means of the last 5 values
Dependent variable Independent vari-
able
Univariate Multiple
B 95% CI β p B 95% CI β p
Cognitive function tests
MOCA total School years 0.446 0.133 to 0.760 0.350 0.006 0.446 0.133 to 0.760 0.350 0.006
TMT-A time Age 1.763 0.717 to 2.809 0.525 0.002 1.798 0.831 to 2.764 0.536 0.001
Biologic vs MTX 6.076 − 0.012 to 12.163 0.343 0.030 6.345 1.252 to 11.432 0.359 0.016
Carotid plaque 
(left)
9.506 0.623 to 18.388 0.365 0.037 4.344 − 3.891 to 12.580 0.167 0.290
TMT-B time Age 3.007 0.949 to 5.064 0.492 0.006 3.007 0.949 to 5.064 0.492 0.006
VST-A time Disease duration 0.341 0.037 to 0.645 0.282 0.029 0.256 − 0.108 to 0.619 0.193 0.163
MRI vascular 
lesions
3.572 1.103 to 6.041 0.398 0.006 4.362 1.827 to 6.897 0.476 0.001
VST-B time Age 0.308 0.058 to 0.559 0.308 0.017 0.493 0.155 to 0.830 0.385 0.005
School years − 0.911 − 1.722 to − 0.100 − 0.283 0.028 − 0.731 − 1.539 to 0.078 − 0.227 0.076
VST-C time Age 0.819 0.369 to 1.268 0.432 0.001 0.819 0.369 to 1.268 0.432 0.001
School years − 1.717 − 3.252 to − 0.181 − 0.282 0.029 − 0.751 − 2.004 to 1.101 − 0.114 0.418
Carotid plaque 
(right)
4.709 0.119 to 9.298 0.260 0.045 1.414 − 3.256 to 6.084 0.078 0.547
WAIS total Age − 0.573 − 0.907 to − 0.239 − 0.411 0.001 − 1.098 − 1.705 to − 0.491 − 0.604 0.001
School years 2.042 0.995 to 3.089 0.456 <0.001 0.574 − 0.756 to 1.904 0.138 0.386
cIMT (right) − 144.84 − 269.887 to 
19.792
− 0.291 0.024 − 93.847 − 204.589 to 
16.895
− 0.189 0.095
Carotid plaque 
(left)
− 3.533 − 6.883 to − 0.183 − 0.267 0.039 − 1.329 − 4.501 to 1.844 − 0.100 0.405
BVRT total School years 0.286 0.142 to 0.430 0.372 < 0.001 0.286 0.142 to 0.430 0.372 < 0.001
MCA CRC (right) 0.050 0.002 to 0.097 0.329 0.041 0.043 0.008 to 0.088 0.312 0.061
BVRT error Age 0.029 0.006 to 0.051 0.247 0.014 0.019 − 0.006 to 0.043 0.192 0.129
School years − 0.132 -0.204 to − 0.060 − 0.348 < 0.001 − 0.132 − 0.204 to − 0.060 − 0.348 < 0.001
Depression/anxiety tests
STAIS School years − 1.410 − 2.057 to − 0.763 − 0.497 < 0.001 − 1.410 − 2.057 to − 0.763 − 0.497 < 0.001
Carotid plaque 
(right)
2.168 0.027 to 4.303 0.257 0.047 0.842 − 1.255 to 2.940 0.100 0.425
Carotid plaque 
(left)
2.200 0.073 to 4.327 0.262 0.043 1.052 − 1.022 to 3.126 0.125 0.314
STAIT School years − 1.295 − 2.205 to − 0.384 − 0.350 0.006 − 0.887 − 1.800 to 0.026 − 0.242 0.057
mESRa 0.290 0.076 to 0.503 0.338 0.009 0.057 − 2.980 to 0.413 0.076 0.749
mDAS28a 4.482 0.725 to 8.239 0.302 0.020 1.207 − 3.090 to 5.503 0.089 0.576
Carotid plaque 
(left)
3.267 0.525 to 6.008 0.299 0.020 3.480 0.247 to 6.713 0.318 0.036
BDI School years − 1.217 − 1.922 to − 0.511 − 0.413 0.001 − 1.217 − 1.922 to − 0.511 − 0.413 0.001
MCA CRC (left) − 0.246 − 0.474 to − 0.019 − 0.393 0.035 0.219 − 0.455 to 0.016 − 0.426 0.065
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measures and categories that allow comparisons with pop-
ulation norms (e.g., European Health Survey) for alcohol 
and tobacco consumption as well as for educational levels 
(ISCED categories) is suggested in further studies. Finally, 
we were unable to perform Bonferroni corrections.
In conclusion, our study suggests that RA patients had 
significant cognitive impairment as determined by multi-
ple tests. Various domains of cognitive dysfunction may be 
associated with age, lower education, disease duration and 
activity, inflammatory markers, primarily the mental com-
ponents of SF-36 and some measures of vascular pathology. 
From the practical point of view, RA patients, especially 
those with higher age, lower education, sustained disease 
activity, should be evaluated for cognitive dysfunction by 
any tests used in our study and also by others. Although 
some anti-rheumatic agents may impair cognitive function, 
the control of inflammation by MTX and biologics in asso-
ciation with tailored behavioral-cognitive therapies may 
benefit our RA patients.
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